Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)

Sponsor
Li Zhang
Study ID
NCT02006043
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

Study Details

evaluate Erlotinib efficacy and safety as the 2nd/3rd line treatment in advanced or recurrent NSCLC with EGFR wild type and without c-met expression

Key Dates

First listed
Dec 9, 2013
Start date
Dec 31, 2013
Status verified
Jul 2015
Primary completion
Dec 31, 2016

Study Design

Enrollment
54 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Erlotinib 150mg/day taken orally
    Erlotinib 150mg/day taken orally until disease progression or intolerable toxicities

Primary Outcome Measure

6 months PFS rate [ Time Frame: at when last patient enrolled 6 months ]

Central Contacts

Related Studies